methyl 3-nitropyrid-2-one-1-butyrate | 351412-08-3

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: methyl 3-nitropyrid-2-one-1-butyrate
• 英文别名: Methyl 4-(3-nitro-2-oxopyridin-1-yl)butanoate
• CAS: 351412-08-3
• 化学式: C₁₀H₁₂N₂O₅
• 分子量: 240.216
• InChiKey: KVVNGVOQMGERPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  92.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-溴丁酸甲酯 生成 methyl 3-nitropyrid-2-one-1-butyrate
  参考文献：
  名称：

  Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin

  摘要：

  化合物公式（I）或其药学上可接受的盐或衍生物；其中变量如说明书中所定义。这些化合物在治疗由VCAM-1和/或纤维连接蛋白与整合素受体α4β1相互作用介导的疾病中有用。还描述和声明了药物组合物和使用或治疗方法。

  公开号：

  US20030181498A1

文献信息

• BICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF THE INTERACTION BETWEEN THE INTEGRIN ALPHA4BETA1 RECEPTOR AND VCAM-1 AND/OR FIBRONECTIN
  申请人：AstraZeneca AB

  公开号：EP1272487A1

  公开（公告）日：2003-01-08
• [EN] BICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF THE INTERACTION BETWEEN THE INTEGRIN ALPHA4BETA1 RECEPTOR AND VCAM-1 AND/OR FIBRONECTIN<br/>[FR] COMPOSES HETEROARYLES BICYCLIQUES UTILISES COMME INHIBITEURS DE L'INTERACTION ENTRE LE RECEPTEUR ALPHA4BETA1 DE L'INTEGRINE ET VCAM-1 ET/OU LA FIBRONECTINE
  申请人：ASTRAZENECA AB

  公开号：WO2001053295A1

  公开（公告）日：2001-07-26

  A compound of formual (I) or pharmaceutically acceptable salts or derivatives thereof; wherein variables are as defined in the specification. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor α4β1. Pharmaceutical compositions and methods of use or treatment are also described and claimed.
• Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin
  申请人：AstraZeneca AB

  公开号：US20030181498A1

  公开（公告）日：2003-09-25

  A compound of formual (I) or pharmaceutically acceptable salts or derivatives thereof; wherein variables are as defined in the specification. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor &agr; 4 &bgr; 1 . Pharmaceutical compositions and methods of use or treatment are also described and claimed.

  化合物公式（I）或其药学上可接受的盐或衍生物；其中变量如说明书中所定义。这些化合物在治疗由VCAM-1和/或纤维连接蛋白与整合素受体α4β1相互作用介导的疾病中有用。还描述和声明了药物组合物和使用或治疗方法。